Literature DB >> 12424616

A novel 'sort-suicide' fusion gene vector for T cell manipulation.

B Fehse1, O S Kustikova, Z Li, A Wahlers, W Bohn, W R Beyer, D Chalmers, P Tiberghien, K Kühlcke, A R Zander, C Baum.   

Abstract

Retroviral suicide gene vectors have successfully been used in clinical studies to improve the safety of adoptive immunotherapy with allogeneic T lymphocytes in the treatment of malignant and viral diseases. At the same time these studies have revealed several problems that are yet to be resolved including impaired T cell function due to long ex vivo culture. Here we present new retroviral vectors co-expressing truncated CD34, a gene transfer marker which ensures rapid enrichment of transduced cells using commercially available GMP-approved devices, and a splice-corrected variant of Herpes simplex virus thymidine kinase (scHSVtk) which confers high sensitivity to the prodrug ganciclovir. We show that a retroviral hybrid vector, MP71, based on the myeloproliferative sarcoma virus (MPSV) and the murine embryonic stem cell virus (MESV), encoding a tCD34/scHSVtk fusion protein mediates high expression of the 'sort-suicide' selection marker, thereby allowing for highly efficient purification and selective elimination of transduced cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424616     DOI: 10.1038/sj.gt.3301828

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Authors:  C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet
Journal:  Gene Ther       Date:  2014-11-13       Impact factor: 5.250

2.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

3.  In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Authors:  Céline Leboeuf; Laurent Mailly; Tao Wu; Gaetan Bour; Sarah Durand; Nicolas Brignon; Christophe Ferrand; Christophe Borg; Pierre Tiberghien; Robert Thimme; Patrick Pessaux; Jacques Marescaux; Thomas F Baumert; Eric Robinet
Journal:  Mol Ther       Date:  2013-12-06       Impact factor: 11.454

4.  Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY.

Authors:  Sascha Kretschmann; Stefanie Herda; Heiko Bruns; Josefine Russ; Edith D van der Meijden; Ursula Schlötzer-Schrehardt; Marieke Griffioen; Il-Kang Na; Andreas Mackensen; Anita N Kremer
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

Review 5.  Contributions of gene marking to cell and gene therapies.

Authors:  Cecilia N Barese; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2011-05-05       Impact factor: 5.695

6.  An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy.

Authors:  Isabel Vogler; Sebastian Newrzela; Sylvia Hartmann; Nadine Schneider; Dorothee von Laer; Ulrike Koehl; Manuel Grez
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

7.  Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene.

Authors:  Hong Zhan; Kimberly Gilmour; Lucas Chan; Farzin Farzaneh; Anne Marie McNicol; Jin-Hua Xu; Stuart Adams; Boris Fehse; Paul Veys; Adrian Thrasher; Hubert Gaspar; Waseem Qasim
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

8.  Retroviral gene therapy in Germany with a view on previous experience and future perspectives.

Authors:  Michael A Morgan; Melanie Galla; Manuel Grez; Boris Fehse; Axel Schambach
Journal:  Gene Ther       Date:  2021-03-22       Impact factor: 5.250

9.  Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens.

Authors:  Anna Luise Bernhardt; Julia Zeun; Miriam Marecek; Hannah Reimann; Sascha Kretschmann; Judith Bausenwein; Edith D van der Meijden; Margarete M Karg; Tabea Haug; Lisa Meintker; Gloria Lutzny-Geier; Andreas Mackensen; Anita N Kremer
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.